{
  "docId": "019de075-cd17-7685-9273-fb1c731af40f",
  "docSlug": "16b2d7592f4634ac7cd717a996934f07",
  "documentTitle": "Theravance Biopharma | Results Presentation Deck | 35 slides",
  "authorId": "theravance-biopharma",
  "authorName": "Theravance Biopharma",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 17,
  "pageCount": 35,
  "prevPage": 16,
  "nextPage": 18,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a classic 'problem vs. solution' or 'market gap vs. strategic imperative' structure.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-cd17-7685-9273-fb1c731af40f/17",
  "deckHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f",
  "deckJsonHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f.json",
  "deckAnchorHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f#slide-17",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.45,
        "x": 0.52,
        "y": 0.35
      },
      "kind": "list",
      "text": "Achieve market leadership; Deliver considerable quality of life improvements; Improve rates of compliance and persistence; Significantly expand the percentage of MSA patients treated.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8f5eb2e9-f04f-4409-922d-9422d020256c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.45,
        "x": 0.05,
        "y": 0.35
      },
      "kind": "list",
      "text": "No approved therapy has demonstrated a durable effect on nOH symptoms; In about half of patients with nOH, supine hypertension complicates management; Many MSA patients remain inadequately managed; Long-term adherence remains low.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f4d51786-9272-4985-beca-c1052e573fb2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "1. NORTHERA® (droxidopa) [package insert]... 5. Kymes, Autonomic Neuroscience: Basic and Clinical, 2020. MSA, multiple system atrophy; nOH, neurogenic orthostatic hypotension; OHSA, Orthostatic Hypotension Symptom Assessment.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "534508ce-d435-4b8a-926d-592cfcae9678",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Ampreloxetine’s Potential for MSA Patients: Highly Differentiated Therapy Delivering Significant Market Expansion",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "211e8c49-5a19-465d-9db1-0211bd4b05de",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Thesis archetype",
      "slug": "thesis-archetype",
      "agent": null,
      "layer": "slide",
      "matchId": "ceaca6e3-f2bc-488a-b8c5-6671320f31ae",
      "evidence": "The slide presents a clear value proposition and market opportunity.",
      "confidence": 0.8
    }
  ],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "c1d88c51-10f4-46d5-a364-dc42d10adfae",
      "evidence": "Side-by-side list comparison of market problems vs. product goals.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 18,
      "from": 11,
      "beatId": "ae4646ce-73d8-418d-9390-888b787632a7",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The document presents the company's progress and potential for YUPELRI and Ampreloxetine",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 17,
      "from": 10,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "f11bf40d-c1c5-42f1-a514-3da6d8f2856f",
      "evidence": "The document highlights the significant unmet need for MSA patients",
      "position": 1,
      "objective": "Emphasizing the cost of inaction for MSA patients",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}